

Egetis Therapeutics Q1 - Emcitate is now launched in Germany

Egetis delivered sales along expectations with reasonable cost control, and more importantly, the German launch is underway following the European approval in February, supported by the earlier European Thyroid Association guidelines in August 2024. We look forward to feedback from the launch and the publication of recent trial results in Brazil (June) over the coming months.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Egetis Therapeutics Q1 - Emcitate is now launched in Germany